In focus · trending topic

MRSA

18 stories · following the connections

ContraFect to Present New Data on CF-301 at ID Week 2017

By Nasdaq OMXSep 29, 2017, 11:00 AM UTC

ContraFect to Present at The MicroCap Conference

By Nasdaq OMXSep 28, 2017, 11:00 AM UTC

Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

By Nasdaq OMXSep 18, 2017, 12:01 PM UTC

ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

By Nasdaq OMXSep 13, 2017, 11:00 AM UTC

Phoenix Based BioNovelus Announces a New Product for the Health Disinfectant Industry

By Nasdaq OMXJun 22, 2017, 11:00 AM UTC

Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI

By Nasdaq OMXMay 2, 2017, 1:39 PM UTC

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

By Nasdaq OMXMar 2, 2017, 1:01 PM UTC

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

By Nasdaq OMXMar 2, 2017, 1:01 PM UTC